Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.70 |
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | HTR1B | P28222 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | HTR2B | P41595 | 4/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.46 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | HTR1E | P28566 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR5A | P47898 | 2/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR1F | P30939 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | POLM | Q9NP87 | 2/20 | 0.43 |
| ▸ | POLK | Q9UBT6 | 2/20 | 0.43 |
| ▸ | POLL | Q9UGP5 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27084761 | 1.00 | HTR2A (0.70) | HTR2AHTR1AHTR1BHTR2CHTR2B | |
| SCHEMBL29832041 | 1.00 | HTR2A (0.70) | HTR2AHTR1AHTR1BHTR2CHTR2B | |
| SCHEMBL27085129 | 0.99 | HTR2A (0.68) | HTR2AHTR1AHTR1BHTR2CHTR2B | |
| SCHEMBL25790828 | 0.92 | HTR2A (0.59) | HTR2AHTR1AHTR1BHTR2CHTR2B | |
| SCHEMBL27085057 | 0.92 | HTR2A (0.59) | HTR2AHTR1AHTR1BHTR2CHTR2B | |
| SCHEMBL27085099 | 0.91 | HTR2A (0.58) | HTR2AHTR1AHTR1BHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL31634307 | 0.91 | HTR2A (0.58) | HTR2AHTR1AHTR1BHTR2CHTR2B | |
| SCHEMBL27084904 | 0.91 | HTR2A (0.58) | HTR2AHTR1AHTR1BHTR2CHTR2B | |
| SCHEMBL29832524 | 0.89 | HTR2A (0.85) | HTR2AHTR1AHTR1BHTR2CHTR2B | |
| SCHEMBL29168439 | 0.89 | HTR2A (0.85) | HTR2AHTR1AHTR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440573-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | Mydecine Innovations Group Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4255422-A1 | NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | Mydecine Innovations Group Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022120181-A1 | NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | MYDECINE INNOVATIONS GROUP INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120181-A1 | NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | MYDECINE INNOVATIONS GROUP INC. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | HTR2A 1278/4885HTR1A 1749/4885HTR1B 993/4885 |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | PSAP, ABCG2, PSAT1 | HTR2A 768/4885HTR1A 922/4885HTR1B 418/4885 |
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | HTR2A 53/4885HTR1A 181/4885HTR1B 324/4885 |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | HTR2A 1201/4885HTR1A 1662/4885HTR1B 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.